EGFR again, provides much promise as a potential target, with preclinical HNSCC models demonstrating that radiolabelled Panitumumab and Cetuximab—both anti-EGFR monoclonal antibodies—exhibited good tumor targeting efficacy with some tumor growth inhibition [97]. Here, EGFR is linked to neoplasm.